Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Hanwha Chemical Corporation (KOSPI: 09830) today announced that they have ent ...

Merck has launched a sweeping cost-cutting effort designed to save $3 billion annually by the end of 2027, the company said ...

Facing patent expiration for its blockbuster Keytruda, Merck aims to streamline operations with significant job cuts and ...

Global pharmaceutical company Merck (NYSE:MRK) in Q2 CY2025, but sales fell by 1.9% year on year to $15.81 billion. The ...

Merck has characterized its cost-cutting initiative as more of a reallocation of resources to support other, higher-growth ...

Facing an end to Keytruda's market exclusivity, the company will cut $3 billion in costs that it plans to redeploy in support ...

Merck & Co., Inc. (NYSE:MRK) is one of the most undervalued blue chip stocks to buy according to hedge funds. On July 21, ...

Drug maker Merck announced Tuesday it will embark on an initiative to cut $3 billion in costs 2027, including an undisclosed ...

The multiyear effort comes as Merck prepares to offset revenue losses from the upcoming patent expiration of its blockbuster ...

Carol Ferguson, 908-423-4465 or Hanwha Chemical Corp: Media: HyukBum Kwon, +82-2-729-3127 or Investor: JaeHong Jeon, +82-2-729-4016 KEYWORDS: United States Asia Pacific North America New Jersey ...